Cargando…

TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression

Hepatocellular carcinoma (HCC) is associated with high mortality and the current therapy for advanced HCC, Sorafenib, offers limited survival benefits. Here we assessed whether combining the TLR3 agonist: lysine-stabilized polyinosinic-polycytidylic-acid (poly-ICLC) with Sorafenib could enhance tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Victor, Lim, Tong Seng, Lee, Justin, Steinberg, Jeffrey, Szmyd, Radoslaw, Tham, Muly, Yaligar, Jadegoud, Kaldis, Philipp, Abastado, Jean-Pierre, Chew, Valerie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694987/ https://www.ncbi.nlm.nih.gov/pubmed/26287667

Ejemplares similares

Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands
por: Chew, Valerie, et al.
Publicado: (2013)

Macrophage depletion reduces postsurgical tumor recurrence and metastatic growth in a spontaneous murine model of melanoma
por: Tham, Muly, et al.
Publicado: (2015)

Molecular characterization of hepatocarcinogenesis using mouse models
por: Teoh, Wei Wei, et al.
Publicado: (2015)

Correction: Molecular characterization of hepatocarcinogenesis using mouse models
por: Teoh, Wei Wei, et al.
Publicado: (2023)

Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth
por: Li, Hao, et al.
Publicado: (2019)

Longitudinal metabolic imaging of hepatocellular carcinoma in transgenic mouse models identifies acylcarnitine as a potential biomarker for early detection
por: Yaligar, Jadegoud, et al.
Publicado: (2016)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation
por: Tham, Muly, et al.
Publicado: (2014)

Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma
por: Pin, Yeo Kim, et al.
Publicado: (2015)

Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses
por: Madan-Lala, Ranjna, et al.
Publicado: (2017)

Immune Microenvironment in Tumor Progression: Characteristics and Challenges for Therapy
por: Chew, Valerie, et al.
Publicado: (2012)

Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
por: Qin, Shukui, et al.
Publicado: (2018)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma
por: Li, Jun, et al.
Publicado: (2018)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma
por: Kim, Dong-Ho, et al.
Publicado: (2022)

TLR7 agonist induced repression of hepatocellular carcinoma via the TLR7-IKK-NF-κB-IL6 signaling pathway
por: REN, XINGBIN, et al.
Publicado: (2016)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
por: Saif, Muhammad W., et al.
Publicado: (2011)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Evolving role of Sorafenib in the management of hepatocellular carcinoma
por: Ziogas, Ioannis A, et al.
Publicado: (2017)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Comparison of human B cell activation by TLR7 and TLR9 agonists
por: Hanten, John A, et al.
Publicado: (2008)

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
por: Cheng, Kui, et al.
Publicado: (2015)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
por: Zhang, Jinglin, et al.
Publicado: (2016)

A 12-week aerobic exercise intervention results in improved metabolic function and lower adipose tissue and ectopic fat in high-fat diet fed rats
por: Gopalan, Venkatesh, et al.
Publicado: (2021)

Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality
por: Szmyd, Radoslaw, et al.
Publicado: (2018)

Correction: Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality
por: Szmyd, Radoslaw, et al.
Publicado: (2019)

Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation
por: Minoux, Kate, et al.
Publicado: (2022)

The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer
por: Gu, Junsheng, et al.
Publicado: (2015)

Evaluation of Dietary Effects on Hepatic Lipids in High Fat and Placebo Diet Fed Rats by In Vivo MRS and LC-MS Techniques
por: Yaligar, Jadegoud, et al.
Publicado: (2014)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
por: Shen, Kuan-Yin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tvi1ogu76vredpfdnpfegmf3o5